Leadership Team
Meet our experienced team.
Our team including Roger Bowie, VP of Development, Gildas Lavenant, VP of Development, will be in Barcelona to showcase our capabilities from lead discovery and candidate selection through the manufacture of drug substance for both bioconjugates and complex biologics.
Whether you’re developing a monoclonal antibody (mABs), antibody-drug conjugates (ADCs), oligonucleotide, vaccine, or radioconjugate, come by our booth to discuss your drug development needs with our experts and learn how we can rapidly move your program forward faster.
While you’re at PEGs Europe, make sure to attend our presentation and poster sessions at the event. On Day 1 of the conference at 16:35, our Manager of Protein Engineering, Dr Thomas Cornell, will be giving a talk on optimization and developability.
Thomas Cornell, Ph.D., Senior manager, Protein Engineering, Protein Engineering, Abzena
Tom Cornell gained his Ph.D. from Kings College London in the field of Chemical Biology. He then moved into the biotech startup space and spent almost a decade in preclinical vaccine research and development, focused on subunit vaccines. After working on over 20 protein families, Tom has gained a wealth of protein engineering experience. Tom joined Abzena almost 2 years ago and works within the protein engineering department working on pre-clinical development of antibody-drug candidates.